{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:33:38Z","timestamp":1792510418549,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>Kaposi sarcoma (KS) is a rare disease caused by human herpesvirus-8 (HHV-8) infection, that occurs in the elderly and more often in men. We aimed to compare the clinical and prognostic features of patients with classic and AIDS-related KS who have been followed in our clinic over the last 10 years and to present real-life data in first-line treatment. We retrospectively reviewed the medical records of 73 patients with KS, 57 with classic KS and 16 with acquired immunodeficiency syndrome (AIDS)-related KS, who were followed up at our clinic between January 2014 and December 2023. Information analyzed included demographic characteristics, clinical features, treatment modalities and prognosis of the patients. The median follow-up period was 44 months in the classic KS group and 20 months in the AIDS-related group. The median age at diagnosis of classic KS patients was 67 years and 82.5% of the patients were male. The median age at diagnosis of AIDS-related KS patients was 41 years and all patients were male. The majority of patients had an Eastern Cooperative Oncology Group performance status of 0 or 1, and comorbidities were more common in the classic KS group. The most common site of involvement in both groups was the lower extremity. 48% and 69% of patients with classic KS and AIDS-related KS, respectively, received first-line systemic chemotherapy. All patients with AIDS-related KS received antiretroviral therapy. Paclitaxel was the most preferred first-line agent in both groups. An optimal overall response rate of 78% was achieved in patients with both classic KS and AIDS-related KS. 5-year overall survival was 75% in patients with classic KS and 93% in patients with AIDS-related KS. This real-world, single-center experience provides insight into the management of patients with KS in a developing country and highlights the need to improve access to standard first-line treatment.<\/jats:p>","DOI":"10.1097\/md.0000000000043576","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T23:01:24Z","timestamp":1754089284000},"page":"e43576","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of clinical and prognostic characteristics of patients with classic and AIDS-related Kaposi sarcoma: A single-center experience"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9516-992X","authenticated-orcid":false,"given":"Okan","family":"Aydin","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Ta\u015fcio\u011flu City Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Erciyestepe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Ta\u015fcio\u011flu City Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Emin","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Ta\u015fcio\u011flu City Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclhan","family":"Din\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Ta\u015fcio\u011flu City Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Uysal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Health Sciences, Prof. Dr. Cemil Ta\u015fcio\u011flu City Hospital, \u0130stanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Mustafa","family":"Atci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Ta\u015fcio\u011flu City Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Ert\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Ta\u015fcio\u011flu City Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"\u00c7elik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Ta\u015fcio\u011flu City Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250918","first-page":"342","article-title":"Idiopathic multiple pigmented sarcoma of the skin.","volume":"32","year":"1982","journal-title":"Wiley Online Library M Kaposi CA"},{"key":"R2-20250918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0060-9","article-title":"Kaposi sarcoma.","volume":"5","author":"Cesarman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20250918","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/bjc.1994.370","article-title":"Epidemiological characteristics of Kaposi\u2019s sarcoma prior to the AIDS epidemic.","volume":"70","author":"Kaldor","year":"1994","journal-title":"Br J Cancer"},{"key":"R4-20250918","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2008.06.007","article-title":"Update on classic Kaposi sarcoma therapy: new look at an old disease.","volume":"68","author":"Di Lorenzo","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"R6-20250918","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/cncr.22236","article-title":"Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma.","volume":"107","author":"Brown","year":"2006","journal-title":"Cancer"},{"key":"R7-20250918","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/94.22.1712","article-title":"Risk factors for classical Kaposi\u2019s sarcoma.","volume":"94","author":"Goedert","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R8-20250918","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2018.12.036","article-title":"Diagnosis and treatment of Kaposi\u2019s sarcoma: European consensus-based interdisciplinary guideline (EDF\/EADO\/EORTC).","volume":"114","author":"Lebbe","year":"2019","journal-title":"Eur J Cancer"},{"key":"R9-20250918","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/09546634.2014.971698","article-title":"Recommended surgery of Kaposi\u2019s sarcoma nodules.","volume":"26","author":"Tourlaki","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"R10-20250918","doi-asserted-by":"crossref","first-page":"e12605","DOI":"10.1111\/dth.12605","article-title":"Radiotherapy in the management of classic Kaposi\u2019s sarcoma: a single institution experience from Northeast Turkey.","volume":"31","author":"Kandaz","year":"2018","journal-title":"Dermatol Ther"},{"key":"R11-20250918","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.21873\/anticanres.15181","article-title":"Treatment of AIDS-related Kaposi\u2019s Sarcoma with low-dose radiotherapy - follow-up on 2,305 tumours.","volume":"41","author":"Wulf","year":"2021","journal-title":"Anticancer Res"},{"key":"R13-20250918","doi-asserted-by":"crossref","first-page":"e32866","DOI":"10.1097\/MD.0000000000032866","article-title":"Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: a real-life study.","volume":"102","author":"Paksoy","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R15-20250918","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0140-6736(90)90001-L","article-title":"Kaposi\u2019s sarcoma among persons with AIDS: a sexually transmitted infection?","volume":"335","author":"Beral","year":"1990","journal-title":"Lancet"},{"key":"R16-20250918","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jnci\/djq134","article-title":"Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.","volume":"102","author":"Lodi","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R17-20250918","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2013.53.7126","article-title":"Broader implications of a stage-guided stratified therapeutic approach for AIDS-related Kaposi\u2019s sarcoma.","volume":"32","author":"Krell","year":"2014","journal-title":"J Clin Oncol"},{"key":"R18-20250918","first-page":"CD003256","article-title":"Treatment of severe or progressive Kaposi\u2019s sarcoma in HIV-infected adults.","volume":"8","author":"Gbabe","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-20250918","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0000000000002744","article-title":"A comparative study of classic and HIV-viremic and aviremic AIDS Kaposi sarcoma.","volume":"35","author":"S\u00e9verin","year":"2021","journal-title":"AIDS"},{"key":"R20-20250918","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R21-20250918","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1007\/s10238-023-01246-3","article-title":"Treatment outcomes of patients with classic and AIDS-related Kaposi sarcoma: a single-center real-world experience.","volume":"23","author":"Valcarcel-Valdivia","year":"2023","journal-title":"Clin Exp Med"},{"key":"R23-20250918","first-page":"746","article-title":"Efficacy of chemotherapeutics on classic and non-classic Kaposi sarcoma: a single-center retrospective real-world study.","volume":"21","author":"Oyucu Orhan","year":"2021","journal-title":"Bosn J Basic Med Sci"},{"key":"R24-20250918","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s12094-010-0568-7","article-title":"Fifty-one Kaposi sarcoma patients.","volume":"12","author":"Dogan","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"R25-20250918","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.12349","article-title":"One hundred and five Kaposi sarcoma patients: a clinical study in Xinjiang, Northwest of China.","volume":"28","author":"Wu","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R26-20250918","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jaad.2005.05.041","article-title":"Epidemiological and clinical characteristics of classic Kaposi\u2019s sarcoma in Peru.","volume":"53","author":"Mohanna","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R27-20250918","doi-asserted-by":"crossref","first-page":"E35552","DOI":"10.1097\/MD.0000000000035552","article-title":"A retrospective study of Kaposi\u2019s sarcoma in Hotan region of Xinjiang, China.","volume":"102","author":"Yang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R28-20250918","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1365-4362.1997.00284.x","article-title":"Classic Kaposi\u2019s sarcoma in Greece: a clinico-epidemiological profile.","volume":"36","author":"Stratigos","year":"1997","journal-title":"Int J Dermatol"},{"key":"R29-20250918","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/cancers14030484","article-title":"Therapeutic perspectives in the systemic treatment of Kaposi\u2019s Sarcoma.","volume":"14","author":"Valantin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R30-20250918","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(19)33222-2","article-title":"Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.","volume":"395","author":"Krown","year":"2020","journal-title":"Lancet"},{"key":"R31-20250918","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/09546634.2019.1590520","article-title":"Paclitaxel as first- or second-line treatment for HIV-negative Kaposi\u2019s sarcoma: a retrospective study of 58 patients.","volume":"31","author":"Tourlaki","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R32-20250918","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1468-3083.2011.04404.x","article-title":"Oral etoposide as first-line therapy in the treatment of patients with advanced classic Kaposi\u2019s sarcoma (CKS): a single-arm trial (oral etoposide in CKS).","volume":"27","author":"Tas","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R33-20250918","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1017\/S0950268812000325","article-title":"Epidemiology of classic and AIDS-related Kaposi\u2019s sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005.","volume":"141","author":"Armstrong","year":"2013","journal-title":"Epidemiol Infect"},{"key":"R34-20250918","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2013.51.6757","article-title":"Prospective stage-stratified approach to AIDS-related Kaposi\u2019s sarcoma.","volume":"32","author":"Bower","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:00:39Z","timestamp":1758232839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":30,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043576","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}